[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alzheimer-disease-late-onset\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alzheimer-disease-late-onset":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,52,82,110,140,190],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100489597","chronic-treatment-of-alzheimers-disease-by-gamma-light-and-sound-therapy-100489597",false,"NCT05655195","Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy","Chronic Treatment of Alzheimer's Disease With Gamma Frequency Stimulation","Inclusion Criteria:\n\nSubjects may be enrolled into the study if they meet all of the following criteria:\n\n* Subject is between the ages of 65 - 100.\n* Subject must have mild Alzheimer's disease with a Mini Mental State Exam (MMSE) score of 19-26.\n* Subject is willing to sign informed consent document.\n* If subject is deemed to not have capacity to sign the informed consent, he\u002Fshe will need a legally authorized representative to provide surrogate consent.\n* Able to complete the 1st month of at home stimulation at their primary residence. If subjects plan to spend more than 1 week away from their primary residence during the trial, their inclusion must be assessed by the research team.\n\nExclusion Criteria:\n\nSubjects who meet any of the following conditions will not be enrolled in the study:\n\n* Subjects who do not have healthcare.\n* Subjects who are currently taking amyloid reducing therapy.\n* Subjects who have \\> 4 cerebral microbleeds or 1 macrobleed in their brain\n* Active treatment on a dosage of one or more psychiatric agents (e.g. antidepressants, antipsychotics, etc) for LESS THAN three months (a stable dose for greater than or equal to three months is ok).\n* Subjects who are actively diagnosed with cancer and undergoing cancer-related treatments\n* Subjects who are being treated with N-methyl-D-aspartate (NMDA) receptor antagonists (eg. Memantine).\n* Subjects on medications that lower seizure threshold such as wellbutrin, ciprofloxacin, levofloxacin, etc.\n* Subjects with history of seizure or epilepsy\n* Subjects with clinically significant suicide risk and\u002For suicide attempt in the past 1 year.\n* Subjects with behavioral problems such as aggression\u002Fagitation\u002Fimpulsivity that might interfere with their ability to comply with protocol.\n* Subjects with untreated or unstable depression\n* Active treatment with one or more anti-epileptic agent.\n* Subjects who have had a stroke within the past 24 months.\n* Subjects who have had eye surgery in the last 3 months or are scheduled to have eye surgery in the next 6 months (during the study)\n* Subjects diagnosed with migraine headache.\n* Subjects who have an active implantable medical device including but not limited to implantable cardioverter defibrillator (ICD), deep brain stimulator (DBS), cardiac pacemaker, and\u002For sacral nerve stimulator.\n* Subjects who have profound hearing or visual impairment.\n* Subjects who have a life expectancy of less than 2 years.\n* Subjects who are pregnant.\n* Current or past history of any neurological disorder other than dementia, such as epilepsy, stroke, progressive neurologic disease (e.g. multiple sclerosis) or intracranial brain lesions; and history of previous neurosurgery or head trauma that resulted in residual neurologic impairment.",true,"ALL","65 Years","100 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. The investigator's lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid and tau in the brain, but also improved memory. The investigators developed a light and sound device for humans that stimulates the brain at 40Hz that can be used safely at home. For the present study, 60 participants with mild Alzheimer's disease will be enrolled and will use this light and sound device at-home daily for 6-months. Investigators will measure changes in brain waves with EEG, blood biomarkers, the microbiome via fecal samples, functional and structural MRI scans, memory and cognitive testing, and questionnaires at 3 in-person visits throughout the study. After the 6-month time point, participants will have the option of continuing in the study for at least one year and completing yearly study visits. This study will provide critical insight into extended therapy involving non-invasive 40Hz sensory stimulation as a possible therapeutic strategy for mild to moderate Alzheimer's disease.",[28,29,30,31,32,33],"Alzheimer Disease","Alzheimer Disease, Early Onset","Alzheimer Disease, Late Onset","Alzheimer's Disease (Incl Subtypes)","Alzheimer's","Alzheimer's Disease",[32,35,36,37,38],"Alzheimer","Alzheimer's disease","Light and Sound Stimulation","Tactile Stimulation","RECRUITING","2026-03-24",{"date":42,"type":43},"2026-03-30","ACTUAL",{"date":45,"type":43},"2022-12-14",{"date":47,"type":22},"2026-09-01",{"name":49,"class":50},"Massachusetts Institute of Technology","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":16,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":63,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100335879","china-cognition-and-aging-study-100335879","NCT03653156","China Cognition and Aging Study","China Cognition and Aging Study: a Multi-center, National-wide, Longitudinal Study in China","COAST","Community population: age ≥ 55 years, male or female, with consent to participant the study.\n\nHospital population: subjects are all over 18 years old. Through clinical evaluation, neuropsychological test, imaging examination, blood and cerebrospinal fluid examination, etc, we will comprehensively evaluate the cognitive function and various test measures.\n\n(1) MCI and its subtypes\n\nInclusion criteria:\n\n1. Diagnosis according to 2004 Peterson's MCI criteria.\n2. CDR = 0.5.\n3. Memory loss is prominent, and may also be with other cognitive domain dysfunction.\n4. Insidious onset, slow progress.\n5. Not reaching the level of dementia.\n\nExclusion criteria:\n\n1. With history of stroke and a neurological focal sign, the imaging findings are consistent with cerebral small vessal disease (Fazekas score ≥ 2 points).\n2. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).\n3. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).\n4. Mental and neurodevelopmental retardation.\n5. Contraindications to MRI.\n6. Suffering from a disease that cannot be combined with cognitive examination.\n7. Refuse to draw blood.\n8. Refuse to sign the informed consent at baseline\n\n(2) Sporadic Alzheimer's disease (SAD)\n\nInclusion criteria:\n\n1. Dementia is diagnosed according to the criteria described by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-R). The diagnosis of AD is made using the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) or National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria.\n2. Subjects and their informed persons can complete relevant and follow- up examinations.\n3. Subjects or their authorized legal guardians sign the informed consent.\n\nExclusion criteria:\n\n1. With a family history of dementia.\n2. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).\n3. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).\n4. Mental and neurodevelopmental retardation.\n5. Contraindications to MRI.\n6. Suffering from a disease that cannot be combined with cognitive examination.\n7. Refuse to draw blood.\n8. Refuse to sign the informed consent at baseline\n\n(3) Familial Alzheimer's disease (FAD)\n\nInclusion criteria:\n\n1. Written informed consent obtained from participant or legal guardian prior to any study-related procedures.\n2. Members in FAD pedigree (FAD is defined as at least two first- degree relatives suffer from AD).\n3. Aged 18 (inclusive) or older.\n4. At least two persons who can provide reliable information for the study. Note: Dementia is diagnosed according to the criteria described by DSM-IV-R. The diagnosis of AD is made using NINCDS-ADRDA or NIA-AA criteria. A diagnosis of MCI is assigned according to Petersen criteria.\n\nExclusion criteria:\n\n1. Dementia caused by other factors such as depression, other psychiatric illnesses, thyroid dysfunction, encephalitis, multiple sclerosis, brain trauma, brain tumor, syphilis, acquired immunodeficiency syndrome (AIDS), Creutzfeldt-Jakob disease and other types of dementias such as vascular dementia (VaD), frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), and Parkinson's disease dementia (PDD).\n2. MRI and laboratory tests do not support or rule out a diagnosis of AD.\n3. Severe circulatory, respiratory, urinary, digestive, hematopoietic diseases (such as unstable angina, uncontrollable asthma, active gastric bleeding) and cancer.\n4. Participant has severe psychiatric illness or severe dementia that would interfere in completing initial and follow-up clinical assessments.\n5. With history of alcohol or drug abuse.\n6. Pregnant or lactating women.\n7. No reliable insiders.\n8. Refuse to sign the informed consent at baseline.\n\n(4) Vascular dementia (VaD)\n\nInclusion criteria:\n\nDiagnosis for probable VaD according to NINDS-AIREN diagnostic criteria.\n\nMRI inclusion criteria:\n\nAll patients who meet clinical inclusion criteria should accept MRI scans which include an assessment of hippocampal volume.\n\n1. multiple (≥3) supratentorial subcortical small infarcts (3-20 mm in diameter) with or without any degree of white matter lesion (WML); or moderate to severe WML (Fazekas score ≥ 2), with or without small infarction; or ≥ 1 subcortical small infarct in key regions, such as caudate nucleus, globus pallidus, or thalamus.\n2. no cortical and watershed infarction, hemorrhage, hydrocephalus, or WML with specific causes (such as multiple sclerosis).\n3. no hippocampus or entorhinal cortex atrophy (MTA score = 0 point).\n\nExclusion criteria:\n\n1. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).\n2. Other systemic diseases that can cause cognitive impairment (such as liver insufficiency, renal insufficiency, thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).\n3. With a history of mental illness or those with congenital mental retardation.\n4. Suffering from a disease that cannot be combined with a cognitive examination.\n5. Contraindications to MRI.\n6. Refuse to draw blood.\n7. Refuse to sign informed consent.\n\n(5) Normal control\n\nInclusion criteria:\n\n1. Aged 18 (inclusive) or above.\n2. Normal MMSE and MoCA evaluations. MMSE\\>19 points for illiteracy, \\>24 points for those educated less than 7 years, \\>27 points for those educated equal to or more than 7 years. MoCA\\>13 points for illiteracy, \\>19 points for those educated less than 7 years, \\>24 points for those educated equal to or more than 7 years.\n\nExclusion criteria:\n\n1. Subjects with abnormal MMSE or MoCA scores.\n2. Subjects with a history of cerebral infarction, traumatic brain injury or related manifestations in MRI.\n3. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).\n4. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).\n5. Mental and neurodevelopmental retardation.\n6. Suffering from a disease that cannot be combined with a cognitive examination.\n7. Contraindications to MRI.\n8. Refuse to draw blood.\n9. Refuse to sign the informed consent at baseline.","18 Years",{"count":62,"type":22},100000,"30 Years","OBSERVATIONAL","The aim of this study is to establish and perfect the China Cognition and Aging Study (China COAST) cohort, to clarify the epidemiology, influencing factors, genetic characteristics, pathogenesis, disease characteristics and diagnosis and treatment status of dementia and its subtypes in China. It is of great significance to establish a relatively comprehensive national database of cognitive disorders, improve the clinical diagnosis and treatment level of cognitive disorders, and formulate prevention and treatment strategies for dementia. The primary aims of China COAST are as follows:\n\n1. To use the prospective cohort to establish a large database research platform, so as to provide comprehensive epidemiological data, clinical and neuropsychological evaluation data, biological samples, and laboratory tests and imaging data.\n2. To update the prevalence and incidence rate of dementia and its subtypes every 2-3 years, and clarify the conversion pattern from normal elderly to MCI and from MCI to dementia.\n3. To explore the known or unknown protective and risk factors of dementia and its major subtypes (AD, VaD, other dementia).\n4. To discover new pathogenic genes and susceptible genes of dementia and its major subtypes (AD and VaD), as well as new mutation sites of known pathogenic genes. To study the genetic variation, mutation and polymorphism of PSEN1, PSEN2, APP and APOE genes in dementia patients, and to understand their distribution and roles in the pathogenesis.\n5. To study the biomarkers (body fluid, genetics, imaging) with diagnostic value of MCI, AD (sporadic and familial) and VaD, to define their cut-off values, and to establish prediction models.\n6. To study the diagnostic criteria of cognitive normal, MCI, dementia and their subtypes (clinical and molecular subtypes) in the cohort, and to make psychological assessment scales with high sensitivity and specificity, and in line with the characteristics of Chinese people.\n7. To find potentially modifiable risk factors for dementia and to study the prevention and intervention effect of non-pharmacological treatment on APOE ε4 carriers, MCI and AD or other dementia patients，which included improvements in education, nutrition, health care, and lifestyle changes. This needs a long time follow-up.\n8. To explore the relationship between dementia as well as its major subtype AD and cerebral and systemetic circulatory disorders (for example, mixed dmentia), as well as potential therapeutic strategies.\n9. To carry out investigation and researches about dementia related education, improve the awareness of dementia, and strengthen the management of dementia.\n10. To investigate the level of stigma and discrimination and its influencing factors in patients with Alzheimer's disease and their caregivers.",[67,30,68,69,70,71],"Mild Cognitive Impairment(MCI)","Familial Alzheimer Disease (FAD)","Vascular Dementia (VaD)","Normal Control","Non-Alzheimer Degenerative Dementia","2026-03-19",{"date":74,"type":43},"2026-03-23",{"date":76,"type":43},"2000-01-01",{"date":78,"type":22},"2038-01-01",{"name":80,"class":50},"Capital Medical University",65,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":51},"100449927","early-phase-1-time-in-bed-restriction-in-older-adults-with-sleep-difficulties-with-and-without-risk-for-alzheimers-disease-100449927","NCT05138848","Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease","Slow-wave Sleep Enhancement in Those at Risk for Alzheimer's Disease: Links With Memory, Excitotoxicity, and Plasma A-beta","ALPS","Inclusion Criteria:\n\n1. Age 65-85.\n2. Self-report mean sleep efficiency (the time in bed spent asleep within the time of lights out to final awakening) \\\u003C 90% based on diary and actigraphy estimates and wake time after sleep onset \\> 20 minutes based on diary and actigraphy estimates.\n3. Self-reported normal or corrected-to-normal visual and auditory acuity.\n\nExclusion Criteria:\n\n1. Shift work involving night shift or regular work within the hours of 12am and 6am.\n2. Presence of a chronic condition that significantly affects sleep.\n3. Severe psychiatric condition including major depressive disorder, panic disorder, substance use disorders, and alcohol abuse\u002Fdependence within the past 6 months, or a lifetime history of a psychotic disorder or bipolar I disorder, based on initial online\u002Fphone self-report diagnoses, and subsequently based on a structured psychiatric interview.\n4. Current use of medications affecting sleep such as antidepressants, antipsychotic medications, anticonvulsants, and steroids.\n5. Current use of sedating drugs used at bedtime.\n6. Consumption of \\> 14 alcohol drinks per week or \\> 6 drinks at a single sitting.\n7. Consumption of \\> 3 caffeine drinks per day.\n8. Prior diagnosis of a Central nervous system (CNS) disease, such as multiple sclerosis, stroke, Parkinson's disease, Alzheimer's disease, seizure disorder, delirium or dementia, a loss of consciousness \\> 24 hours, or traumatic brain injury as identified by the Cumulative Illness Rating Scale for Geriatrics (CIRS). Participants who are diagnosed with Alzheimer's disease based on neuropsychological testing will be excluded.\n9. Sleep efficiency \\> 90% and wake time after sleep onset \\\u003C 20 minutes consistent with the rationale of the inclusion criteria described above.\n10. Apnea\u002Fhypopnea index greater than 15 as determined by one night of Apnea Link Plus screening.\n11. Metal in the body. Rationale: Due to the nature of magnetic resonance imaging (MRI), participants cannot have any metal implants in their bodies, cannot have worked in a metal shop or been exposed to metal fragments during combat. Metal dental work (e.g. fillings crowns) may be allowed if compatible with the fMRI scanner.\n12. Claustrophobia. Rationale: Could prevent the participant from completing the MRI scans.\n13. Severe obesity. BMI \\> 40. Rationale: Could prevent the participant from completing the MRI scan.\n14. Near-miss or prior automobile accident \"due to sleepiness\" within the past 12 months. Rationale: reduces the risk of sleepiness-related accidents.\n15. Employed as a commercial driver during the study (for example, bus drivers, train engineers, airplane pilots). Rationale: reduces the risk of sleepiness-related accidents.\n16. A score below 23 on the Telephone Interview for Cognitive Status. Rationale: This cut-off has been demonstrated to differentiate well between individuals with mild cognitive impairment from individuals with dementia who would have decision making impairments (Seo et al. 2011, Archives of Gerontology and Geriatrics). This ensures that decision making abilities are intact.\n17. An Epworth sleepiness score greater than 10. Rationale: ensures that sleepiness is not excessive before starting the intervention that could further increase sleepiness. (Mazzotti, Diego R., et al. \"Is the Epworth Sleepiness Scale sufficient to identify the excessively sleepy subtype of OSA?.\" Chest 161.2 (2022): 557-561; Aurora, R. Nisha, et al. \"Correlating subjective and objective sleepiness: revisiting the association using survival analysis.\" Sleep 34.12 (2011): 1707-1714.)","85 Years",{"count":92,"type":22},116,[94],"EARLY_PHASE1","Dementia caused by Alzheimer's disease affects approximately 5.6 million adults over age 65, with costs expected to rise from $307 billion to $1.5 trillion over the next 30 years. Behavioral interventions have shown promise for mitigating neurodegeneration and cognitive impairments. Sleep is a modifiable health behavior that is critical for cognition and deteriorates with advancing age and Alzheimer's disease. Thus, it is a priority to examine whether improving sleep modifies Alzheimer's disease pathophysiology and cognitive function. Extant research suggests that deeper, more consolidated sleep is positively associated with memory and executive functions and networks that underlie these processes. Preliminary studies confirm that time-in-bed restriction interventions increase sleep efficiency and non-rapid eye movement slow-wave activity (SWA) and suggest that increases in SWA are associated with improved cognitive function. SWA reflects synaptic downscaling predominantly among prefrontal connections. Downscaling of prefrontal connections with the hippocampus during sleep may help to preserve the long-range connections that support memory and cognitive function. In pre-clinical Alzheimer's disease, hyperactivation of the hippocampus is thought to be excitotoxic and is shown to leave neurons vulnerable to further amyloid deposition. Synaptic downscaling through SWA may mitigate the progression of Alzheimer's disease through these pathways. The proposed study will behaviorally increase sleep depth (SWA) through four weeks of time-in-bed restriction in older adults characterized on amyloid deposition and multiple factors associated with Alzheimer's disease risk. This study will examine whether behaviorally enhanced SWA reduces hippocampal hyperactivation, leading to improved task-related prefrontal-hippocampal connectivity, plasma amyloid levels, and cognitive function. This research addresses whether a simple, feasible, and scalable behavioral sleep intervention improves functional neuroimaging indices of excitotoxicity, Alzheimer's pathophysiology, and cognitive performance.",[30,97,98,99,100],"Mild Cognitive Impairment","Sleep","Cognitive Change","Amyloid","2025-12-17",{"date":103,"type":43},"2025-12-19",{"date":105,"type":43},"2022-01-03",{"date":107,"type":22},"2026-05-31",{"name":109,"class":50},"University of Pittsburgh",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":118,"targetDuration":119,"studyType":64,"phases":4,"briefSummary":120,"conditions":121,"keywords":124,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":51},"100550540","multimodal-assesment-of-alzheimer-patients-100550540","NCT06448403","Multimodal Assesment of Alzheimer Patients","Multimodal Assessment of Cognitive Impairment in Alzheimer Patients","MultiAD","Inclusion Criteria:\n\n* MCI and AD according to relevant ICD-criterias.\n* Control cohort is age and gender matched with other cohorts.\n\nExclusion Criteria:\n\n* Uneligibility for any of the planned neuroimagery devices (MRI, EEG)\n* AD diagnosis before the age of 65 (Early-onset AD).\n* Brain tumor\n* Traumtic head injury\n* Earlier neurosurgery\n* Other neyrodegenerative diseases (i.e Parkinson and ALS)\n* Diseases related to inflammation and auto-immunity (i.e MS)",{"count":21,"type":22},"5 Years","The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD).\n\nThe main questions the study aims to answer are:\n\n1. What findings can be used to earlier detect patients that will develop Alzheimers?\n2. Which differences are seen between healthy and cognitively impaired patients?\n3. Which differences are seen between patients with Alzheimers disease?\n\nParticipants will undergo:\n\n* Cognitive tests\n* Magnetic resonance imaging (MRI)\n* Electroencephalography (EEG)\n* Blood sample collection\n* Fecal sample collection\n* A randomized group will undergo polysomnography analysis.",[97,30,122,123],"Cognitive Impairment","Dementia",[125,126,127,128,129,123,130],"Alzheimer Disease (AD)","Mild cognitive impairment (MCI)","Brain Diseases","Nervous System Disorders","Neurodegenerative Diseases","Cognitive impairment","2025-08-04",{"date":133,"type":43},"2025-08-07",{"date":135,"type":43},"2024-07-01",{"date":137,"type":22},"2030-12-29",{"name":139,"class":50},"Norwegian University of Science and Technology",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":146,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":149,"conditions":150,"keywords":176,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":51},"100531692","nyscf-scientific-discovery-biobank-100531692","NCT06203106","NYSCF Scientific Discovery Biobank","Inclusion Criteria:\n\n* Age 30 days or older.\n* Diagnosis and\u002For medical history of a condition, disease, genetic background, or trait of interest or healthy control.\n* Adults with decisional capacity must provide written informed consent unless physical limitations preclude signing.\n* Adults without decisional capacity to consent must a have diagnosis of Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease and Related Dementias (AD\u002FADRD); Batten Disease, Corticobasal Degeneration (CBD), Dementia, Frontotemporal Dementia (FTD), Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson's Disease (PD), Parkinsonism, and\u002For Progressive Supranuclear Palsy, and must provide assent; a legally authorized representative (LAR) must also provide written informed consent.\n* Minors undergoing skin collection for research purposes must have a condition, disease, genetic background, or trait of interest and parental\u002Fguardian consent.\n* Minors undergoing blood, and\u002For saliva collection for research purposes may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent\u002Fguardian to provide consent.\n* Minors transferring biological samples and associated data from a procedure outside of the research may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent\u002Fguardian to provide consent.\n\nExclusion Criteria:\n\n* Wards of the state.\n* For prospective skin samples: history of keloid formation, coagulation disorder, or allergy to the anesthetic.\n* For prospective blood samples: history of coagulation disorder.\n* For all prospective sample collections: 1) Subjects who refuse to adhere to NYSCF's and\u002For a collection site's safety protocol(s) will be excluded; 2) Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.","30 Days",{"count":148,"type":22},10000,"The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use.\n\nThrough this research, researchers hope to identify future treatments or even cures for the major diseases of our time.",[151,152,28,29,30,153,154,123,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175],"ALS","Amyotrophic Lateral Sclerosis","Batten Disease","Corticobasal Degeneration","Frontotemporal Dementia","Huntington Disease","Lewy Body Disease","Multiple Sclerosis","Multiple System Atrophy","Parkinson Disease","Parkinson's Disease and Parkinsonism","Progressive Supranuclear Palsy","INAD","Diabetes","Diabetes Mellitus","Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1","Macular Degeneration","Ovarian Cancer","Cervical Cancer","Uterine Cancer","Vaginal Cancer","Vulvar Cancer","PTSD","Post Traumatic Stress Disorder",[151,152,28,153,154,123,155,156,157,158,159,160,177,162,163,164,178,179,168,180,169,170,171,172,173,174,175],"Parkinsonism","Diabetes Type 1","Diabetes Type 2","Women's Reproductive Cancer","2025-02-27",{"date":183,"type":43},"2025-03-03",{"date":185,"type":43},"2022-11-10",{"date":187,"type":22},"2045-11-10",{"name":189,"class":50},"New York Stem Cell Foundation Research Institute",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":16,"sex":17,"minAge":196,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":51},"100559267","establish-diagnostic-and-prognostic-models-for-preclinical-ad-patients-based-on-multimodal-mri-behavioral-genetic-and-plasma-biomarkers-100559267","NCT06561906","Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers","Inclusion Criteria:\n\n* The inclusion criteria were 50-79 years old and having 8 or more years of education.\n\nExclusion Criteria:\n\n* Participants with a history of stroke, other neurological disorders that could lead to cognitive impairment (Parkinson's disease, encephalitis, epilepsy, brain tumors, etc.), severe anxiety or depression, and contraindications for magnetic resonance imaging (MRI) were not enrolled.","50 Years","79 Years",{"count":199,"type":22},1000,"To establish the diagnostic and prognostic models that could help the preclinical identification of subjects at higher risk of clinical progression to mild cognitive impairment and dementia based on combined features of baseline demographic, cognitive, behavioral, multimodal MRI, genetic, and plasma data.",[30,97,202],"Subjective Cognitive Decline",[204,205,206,207,208],"magnetic resonance imaging","spatial navigation","olfaction","genetic","plasma biomarkers","2024-08-16",{"date":211,"type":43},"2024-08-20",{"date":213,"type":43},"2020-09-01",{"date":215,"type":22},"2027-12",{"name":217,"class":50},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"]